These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 6265032

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Modification of dopaminergic transmission by thyrotropin-releasing hormone.
    Narumi S, Nagawa Y.
    Adv Biochem Psychopharmacol; 1983; 36():185-97. PubMed ID: 6305147
    [Abstract] [Full Text] [Related]

  • 3. The effects of repeated amphetamine administration on the thyrotropin-releasing hormone level. Its release and receptors in the rat brain.
    Jaworska-Feil L, Budziszewska B, Lasón W.
    Neuropeptides; 1995 Sep; 29(3):171-6. PubMed ID: 8538879
    [Abstract] [Full Text] [Related]

  • 4. D-Amphetamine reduces striatal substance P concentrations by presynaptic release of dopamine.
    Pettibone DJ, Wurtman RJ.
    Brain Res; 1980 Mar 31; 186(2):409-19. PubMed ID: 6153555
    [Abstract] [Full Text] [Related]

  • 5. Reduction of rat striatal thyrotropin-releasing hormone receptors produced by repeated methamphetamine administration.
    Nakashima M, Kajita S, Otsuki S.
    Biol Psychiatry; 1989 Jan 15; 25(2):191-9. PubMed ID: 2539202
    [Abstract] [Full Text] [Related]

  • 6. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain.
    Costall B, Marsden CD, Naylor RJ, Pycock CJ.
    Brain Res; 1976 Dec 10; 118(1):87-113. PubMed ID: 990957
    [Abstract] [Full Text] [Related]

  • 7. The effects of thyrotropin releasing hormone on rats with lesions of the mesolimbic and nigrostriatal dopamine systems.
    Andrews JS, Sahgal A.
    Physiol Behav; 1985 Jul 10; 35(1):93-7. PubMed ID: 2997819
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain.
    Jaworska-Feil L, Turchan J, Przewłocka B, Budziszewska B, Leśkiewicz M, Lasoń W.
    J Neural Transm (Vienna); 1999 Jul 10; 106(5-6):395-407. PubMed ID: 10443546
    [Abstract] [Full Text] [Related]

  • 14. Effects of behaviorally active doses of thyrotropin-releasing hormone and its analog MK-771 on dopaminergic neuronal systems in the brain of the rat.
    Yamada K, Demarest KT, Moore KE.
    Neuropharmacology; 1984 Jul 10; 23(7A):735-9. PubMed ID: 6433220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Thyrotropin-releasing hormone (TRH): action mechanism of an enhanced dopamine release from rat striatal slices (author's transl)].
    Narumi S, Nagai Y, Nagawa Y.
    Nihon Yakurigaku Zasshi; 1979 Apr 20; 75(3):239-50. PubMed ID: 119692
    [Abstract] [Full Text] [Related]

  • 18. Dopaminergic substrates of amphetamine-induced place preference conditioning.
    Spyraki C, Fibiger HC, Phillips AG.
    Brain Res; 1982 Dec 16; 253(1-2):185-93. PubMed ID: 6817850
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.